Pathological angiogenesis is a hallmark of cancer and various inflammatory conditions including ocular neovascular diseases (1, 2) . Recent studies have led to the discovery of a growing number of antiangiogenic molecules, some of which are already being evaluated in clinical trials (1, 2) . The most established approach for limiting path ological angiogenesis involves blockade of the vascular endothelial growth factor (VEGF) pathway (3) (4) (5) ; however, several studies have shown that VEGF blockade damages healthy vessels and results in toxic side effects (6, 7) and that interrupting the VEGF blockade induces rapid vascular regrowth in tumors (8) . Clinical trials involving patients with neovascular age related macular degeneration have shown that VEGF blockade has limited effectiveness in some patients (5) . Therefore, several groups have ex plored other targets that could potentially be combined with VEGF blockade (9) (10) (11) . In par ticular, tumorassociated hematopoietic cells are thought to be a promising therapeutic target, es pecially neutralizing Bv8, which promotes both tissuespecific angiogenesis and hematopoietic cell mobilization (10) .
Macrophage CSF (MCSF) (12) is a cytokine required for the differentiation of monocyte lin eage cells (e.g., tissue macrophages, osteoclasts, and microglia) during development (13, 14) . Al though greatly reduced numbers of monocyte lineage cells are present in osteopetrotic (op/op) mutant mice (i.e., mice that possess a mutant csf-1 gene encoding MCSF) (13) , the potential MMP2 (not depicted) expression was detected on the cell surfaces of macrophages. Both of these MMPs are macro phagederived proteases that work with modulating extracel lular matrix (ECM) proteins, such as fibronectin, to remodel vascular structures (24) . Macrophages contribute to pro grammed cell death in temporary hyaloid vessels via Wnt7b (25) ; however, their role in the formation of retinal vascular plexus has not yet been clarified. Therefore, we examined the role of MCSF in developmental angiogenesis by examining the retinal vascular structures of op/op mice, which lack mac rophages stained with Mac1, F4/80, CD45, or isolectin (Fig. 1 , G and H). By postnatal day (P) 2, branching was reduced in the vascular plexus of the op/op retina (Fig. 2, A , B, and K), but the numbers of endothelial tip cells and filopodia (which are regulated by VEGF [26] ) were comparable to those in wild type mice (Fig. 2 J) . Vascular defects in the op/op retina were also detected on P4, as shown by significantly reduced branch ing and insufficient arterialvenous patterning ( (Fig. 2 , E and F), the expression of MMP2 and MMP9 (Fig. 2 I) was decreased in the op/op retina. Presumably because of this decreased proteinase activity, op/op retina showed disor dered fibronectin architecture (Fig. 2, G and H) . To examine the function of MCSF in the postnatal developing retina, wildtype mice were systemically treated with a small molecule tyrosine kinase inhibitor specific for cfms (Ki20227) (27) or intraocularly injected with anti-cfms neutralizing antibodies (AFS98) (28) during the postnatal stage. Both treatments sig nificantly reduced branching by P4, but the number of endo thelial tip cells was comparable to that in control mice (i.e., mice treated with vehicle alone) (Fig. 2 , L-P). The reduction rate for branching points was greater in response to MCSF inhibition than in response to MCSF deficiency, suggesting that some form of compensation occurs in the postnatal op/op retina. When retinas were treated with Ki20227/anti-cfms antibodies, macrophages decreased in number and exhibited insufficient stellate morphology (Fig. 2, L-P) . Thus, these re sults suggest that MCSF contributes to developmental vascu lar remodeling independently of VEGF but does not contribute to the maintenance of adult vasculature.
M-CSF is required for pathological neovascularization but not for recovery of normal vasculature in oxygeninduced retinopathy (OIR) Although normalized vasculature in the later stage of op/op mice suggests that MCSF is not required for the maintenance of stable adult vasculature, we suspected that MCSF might be critical for the induction of pathological neovascularization. The OIR model (29) is a widely used system to examine ocu lar neovascularization, a condition which resembles prolifera tive diabetic retinopathy in humans (30) . In this model, the effects on angiogenesis and lymphangiogenesis have not been evaluated. Recent studies suggest that MCSF plays a key role in the formation of highdensity vessel networks and acts as an "angiogenic switch" in a mouse model of mammary tumors (15, 16) . The inhibition of MCSF by antisense oligonucle otides, small interfering RNAs, or blocking antibodies sup presses the growth of human mammary tumor xenografts in mice (17, 18) . Clodronate liposome, a reagent for depleting macrophages, also inhibits tumor growth (19) . However, the mechanisms underlying the role of MCSF in tumor progres sion, particularly with regards to tumor lymphangiogenesis and tumor selectivity, have not been fully dissected.
Osteosarcoma, the most common primary bone tumor, is defined as a malignant tumor derived from mesenchymal or stromal cells with highly metastatic capacities, particularly in the lung and liver (20) . Multimodal treatment, often consisting of aggressive chemotherapy combined with radical surgical resection (e.g., limb amputation), has traditionally been the mainstay of osteosarcoma management; however, the progno sis of osteosarcoma patients has not improved significantly in recent years (20) . Lack of an appropriate animal model for hu man osteosarcoma has hampered the development of an effec tive antiosteosarcoma therapy.
In this study, we used op/op mice to demonstrate that MCSF contributes to both vascular and lymphatic develop ment. Furthermore, our data show that MCSF is required for retinal pathological neovascularization but not for the maintenance of stable adult vasculature or lymphatics. Using a newly established mouse model of osteosarcoma, we show that MCSF inhibition selectively suppresses tumor angio genesis and lymphangiogenesis. In contrast to VEGF block ade, the interruption of MCSF inhibition does not promote rapid tumor regrowth. These findings indicate that MCSFtargeted therapy is an ideal strategy for the treatment of ocular neovascular diseases and cancer.
RESULTS

M-CSF contributes to developmental vascular remodeling but not to maintenance of adult vasculature
Postnatal retinal vascular development, a widely used model for studying sprouting angiogenesis, can be used to study path ological angiogenesis (e.g., the formation of blood vessels in tumors) (21, 22) . We first characterized macrophages in a retinal angiogenesis model. Macrophages stained with Mac1 were found in avascular and vascularized areas and were readily dis tinguished from desminstained pericytes (Fig. 1 A) . Active vascular remodeling takes place in capillary areas during the pruning of vascular capillary components (23) . Macrophages in these areas had large expanded cytoplasms and contained vesi cles positive for PECAM1 (Fig. 1 B) in contrast to the lean bodies observed in arterial areas (Fig. 1 C) . Immunostaining of laminin revealed the presence of basal lamina between macro phages and pericytes (Fig. 1 D) . We then examined several angiogenic factors and were unable to detect VEGF in macro phages via in situ hybridization (ISH; Fig. 1 E) . Furthermore, abundant matrix metalloproteinase (MMP) 9 ( Fig. 1 F) and or intraocularly injected with anti-cfms neutralizing anti bodies during neovascularization. Both avascular and NVT areas dramatically decreased in response to these treatments, relative to mice treated with vehicle or control IgG (Fig. 3 , J-O and V). The number of macrophages surrounding NVT areas dramati cally decreased in mice treated with Ki20227/anti-cfms anti bodies, as well as in op/op mice (Fig. 3 , R-U [quantification not depicted]). Retinas in MMP9 / mice exhibited signifi cantly fewer NVTs but increased physiological revasculariza tion (unpublished data). In contrast, treatment with SU1498, a potent and selective inhibitor of VEGFR2, nonselectively suppressed both pathological and physiological angiogenesis ( Fig. 3 , P, Q, and V). Collectively, these data suggest that tar geting macrophage/ECMrelated molecules selectively inhibits pathological neovascularization but does not affect the recov ery of normal vasculature in the OIR model.
M-CSF contributes to postnatal lymphatic development
Macrophages are thought to play important roles in lymphan giogenesis, particularly in macrophage subpopulations that ex press LYVE1, a marker of lymphatics. In these subpopulations, central area of established vasculature is obliterated by hyperoxic insult, creating an ischemic area. After mice are returned to room air, revascularization occurs and the normal vasculature is recovered, although some vessels (i.e., neovascular tufts [NVTs]) proliferate abnormally toward the vitreous body (Fig. 3 A) . Increased expression of csf-1, vegf-a, and the cfms receptor (csfr-1) was observed during neovascularization in the OIR model (Fig. 3, B-D) . In addition, csfr-1 expression was higher in FACSsorted Mac1 + cells than in Mac1  cells (Fig. 3 E) , suggesting that csfr-1 is specific to macrophages. These data also indicate that csfr-1 expression in tissues largely reflects the num ber of macrophages. There was no significant difference in the vasoobliterated areas of wildtype and op/op retina on P11 in the OIR model (Fig. S2, A, B , E, F, and I), suggesting that vascular resistance to hyper oxygen insult was not altered in op/op retina. Similarly, Ki20227 treatment did not alter vascular resistance to hyper oxygen insult (Fig. S2 , C, D, G, H, and J). On P16, the op/op retina exhibited a dramatic decrease in NVTs but an increase in physiological revascularization (Fig. 3 , F-I and V). To confirm the role of MCSF in neovasculariza tion, wildtype mice were systemically treated with Ki20227 with AX cells and were accompanied by intratumor high density vascularization and abundant peritumoral lymphatics (Fig. 5, A-E) . To analyze the effects of MCSF inhibition, Ki20227 or anti-cfms antibodies were administered via daily subcutaneous injections. Mice treated with Ki20227 or anti-cfms antibodies exhibited suppressed tumor growth, dramatically decreased tumor vascularization and peritumoral lymphatics (Fig. 5 , A-G and Q-T), and decreased BrdU incorporation by tumor cells relative to control mice (Fig. 5 , H-J, U, and V). Although small calcified loci were detected at the center of tumors in vehicletreated mice, early and massive calcified loci were detected throughout the trans planted tumors in mice treated with Ki20227 or anti-cfms antibodies (Fig. 5, K-M ). Mice treated with Ki20227 or anticfms antibodies exhibited dramatically decreased peritu moral LYVE1 + macrophages and perivascular macrophages infiltrated into tumors compared with control mice (Fig. 5 , N-P). In contrast to VEGFR2 neutralization (11), continu ous treatment of adult mice with Ki20227 or anti-cfms antibodies for a period of 56 d did not affect healthy vascular and lymphatic systems outside the tumor (Fig. 5 W) . Collec tively, MCSF inhibition selectively suppressed tumor angio genesis and lymphangiogenesis.
We performed in vitro culture experiments to determine if the tumorsuppressing effects of cfms inhibition are medi ated by effects on tumors or on recruited monocytes. Hypoxic growth resulted in osteogenic differentiation and MCSF expression and decreased proliferation in cultured AX cells (Fig. S4 , A-C). However, supplementation with 100 nM Ki20227, a sufficient dose for the inhibition of cfms kinase (27) , did not affect osteogenic differentiation or proliferation in AX cells (Fig. S4, A and F) . Supplementation with 100 nM Ki20227 inhibited survival and proliferation in cultured BM mononuclear cells (MNCs; unpublished data). To identify the potential ligand-receptor interactions resulting from MCSF signaling between tumors and macrophages, we compared the expression of MCSF and cfms in cultured AX cells and in BM MNCs. Cultured AX cells exhibited high levels of csf-1 expression, compared with cultured MNCs (Fig. S4 D) , but relatively lower levels of csfr-1 (Fig. S4 E) expression. These in vitro data suggest that the tumorsuppressing effects of MCSF inhibition are mediated by effects on recruited mac rophages but do not directly affect AX cells. the number of LYVE1 + macrophages correlate with the extent of tissue lymphangiogenesis (31) . In the developing trachea, the emergence of LYVE1  macrophages preceded that of LYVE1 + macrophages, and most LYVE1 + macrophages were present in vascularized areas (Fig. 4, A-C) . Furthermore, cfms expression was more abundant in LYVE1 + than in LYVE1  macrophages (Fig. 4 D) . As it is likely that MCSF/ cfms signaling contributes to lymphangiogenesis, we exam ined developing lymphatic structures in op/op mice. At P15, the number of LYVE1  and LYVE1 + macrophages dramat ically decreased in the tracheas and ears of op/op mice, and reduced lymphatic branching was observed (Fig. 4, E-H , O, and P). Furthermore, tissue fluids drained more slowly in the limbs and ears of op/op mice (Fig. 4, I-L) . By P15, some op/op mice exhibited apparent perforation of the dorsal tracheal sur face (Fig. 4, E and F, insets) , presumably as a result of abnor mal lymphatic drainage. Although hydrocephalus is thought to underlie the high lethality of op/op mice at this stage (14) , tracheal perforation could also lead to death. However, op/op mice that survived for 3 mo possessed normal lymphatic sys tems (unpublished data). The op/op mice exhibited normal embryonic lymphangiogenesis but lacked LYVE1 + macro phages (Fig. 4, M and N; and Fig. S3 ). Treatment with Ki20227 or anti-cfms antibodies decreased both LYVE1  and LYVE 1 + macrophages and reduced the extent of lymphatic branch ing (Fig. 4, R and S) . Collectively, these data show that MCSF contributes to the appearance of LYVE1 + macrophages and postnatal lymphatic development.
M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis
The mechanisms underlying developmental angiogenesis and lymphangiogenesis may impact tumor angiogenesis and lymphangiogenesis (1, 2, 32); thus, we hypothesized that MCSF-targeted therapies selectively suppress tumor angio genesis and lymphangiogenesis. These effects may be espe cially noticeable in osteosarcomas, which express high levels of MCSF (33) . Therefore, we analyzed a mouse model of osteosarcoma, in which mice were transplanted with a newly established osteosarcoma cell line, AX (unpublished data). we compared the antitumor effects of MCSF inhibition and VEGF inhibition in three differential therapeutic protocols, including the protocol that involved interruption of administra tion in addition to vehicle or continuous treatment (Fig. 7 Q) . Although continuous SU1498 administration greatly inhib ited tumor growth and vascular/lymphatic growth in tumors, as did Ki20227 administration, interruption of SU1498 treat ment resulted in rapid vascular and lymphatic regrowth (Fig. 7,  S-U) . In contrast, interruption of Ki20227 administration greatly reduced vascular and lymphatic growth (Fig. 7, V-X) . Although the interruption of SU1498 treatment did not suffi ciently inhibit tumor metastasis and cancer death, sustained effectiveness was observed after the interruption of Ki20227 administration (Fig. 7, Y , Z, and AA).
DISCUSSION
We used op/op mice to demonstrate that MCSF-dependent macrophages contribute to both vascular and lymphatic devel opment. Furthermore, we show that MCSF is required for pathological neovascularization but not for the recovery of normal vasculature in OIR. Deficiency in MCSF does not affect the maintenance of stable adult vasculature and lymphat ics. In mice with osteosarcoma, MCSF inhibition selectively suppressed tumor angiogenesis and lymphangiogenesis and de creased tumor regrowth after the interruption of treatment.
Our data showing the highly specific effects of MCSF inhibition on pathological angiogenesis and lymphangiogen esis are supported by the observation that no detectable abnor malities in adult vascular and lymphatic systems were found in op/op mice. In contrast to the effects of VEGF blockade, interruption of MCSF inhibition did not promote rapid tumor regrowth but rather improved the prognosis relative to treatment with a vehicle. This difference might be a result of the effects of MCSF inhibition on the "sleeves" of the basement membrane. These socalled sleeves are conserved during VEGF blockade and assist with rapid vascular regrowth in primary tumors (8) . The physiological role of retinal mac rophages in developmental vascular remodeling, but not in angiogenic sprouting, suggests that MCSF inhibition and VEGF blockade target different factors. Indeed, the tumor suppressive effects of MCSF inhibition are independent of VEGF signaling. Furthermore, a recent study showed that tumor refractoriness to antiVEGF treatment is mediated by Mac1 + Gr1 + myeloid cells (37) , suggesting that MCSFtargeted therapy may serve as a useful secondary therapy in patients who are resistant to VEGF blockade.
We showed that retinal macrophages express high levels of MMP2 and MMP9 but not VEGF. These expression patterns
M-CSF inhibition suppresses tumor metastasis of mouse osteosarcoma and improves prognosis
We then examined the effects of Ki20227 and anti-cfms an tibodies on tumor metastasis and disease prognosis. We per formed a functional analysis of tumorassociated lymphatics by examining the dye efflux capacity of transplanted tumors. Tumors in mice treated with Ki20227 or anti-cfms antibod ies exhibited significantly higher levels of dye retention com pared with tumors in vehicletreated mice (Fig. 6, A-C and  V) . In vehicletreated mice, transplanted AX cells spread to the liver and lung (Fig. 6, D , G, J, M, P, and S), two major metastatic sites in human osteosarcoma (20) . Approximately 20% of mice remained alive 56 d after tumor cell inoculation (Fig. 6 X) . However, metastases were dramatically suppressed in mice treated with Ki20227 or anti-cfms antibodies (Fig. 6 , D-U and W), and >90% of these mice survived for 56 d (Fig. 6 X) . Aside from its role in MCSF/cfms signaling, VEGF/Flt1 plays a profound role in the recruitment of mac rophages and the progression of cancer in various models (11, (34) (35) (36) . To examine the involvement of VEGF/Flt1 sig naling in our established mouse osteosarcoma, AX cells were transplanted into mice deficient in Flt1 tyrosine kinase (Vegfr1 tk / ). Deficiency in Flt1 tyrosine kinase did not affect the number of recruited macrophages (Fig. S5, A and B) , tumor growth (Fig. S5 C) , or metastasis (Fig. S5, D-G) , suggesting that macrophages are less dependent on VEGF/Flt1 signaling in this model than in other cancer models.
M-CSF inhibition disorganizes extracellular matrices and suppresses tumor progression when treatment is interrupted
To explore the differences between MCSF inhibition and VEGF inhibition, we compared the antitumor effects of two small tyrosine kinase inhibitors, Ki20227 and SU1498. Vascular ECM structures stained by fibronectin (which has the poten tial to induce tumor vascular regrowth) (8) retained the spatial distribution surrounding endothelial cells treated with SU1498 or a vehicle (Fig. 7, A-F) . In contrast, these structures were irregularly deposited throughout the tumors in Ki20227 treated mice (Fig. 7, G-L) , suggesting a disturbance in the remodeling or degradation of ECM scaffolds. In contrast to Ki20227, SU1498 did not affect tumorassociated macro phages (Fig. 7, M and N) . Tumors transplanted into MMP9 / mice exhibited irregularly deposited ECM structures, which is similar to tumors transplanted into Ki20227treated mice (Fig.  7 , O and P), and exhibited decreased tumor growth (not de picted). These data suggest that the proteases produced by macrophages contribute to matrix remodeling. Furthermore, , IHC for GFP (green) and TOTO3 (blue; G-I and P-R), or hematoxylin and eosin staining (J-L and S-U) in the liver or lung 56 d after tumor inoculation (representative images of five independent experiments). Note that the multiple metastatic masses (arrowheads) in control mice were completely absent in mice treated with Ki20227/anti-c-fms IgG. (V-X) Quantification (mean ± SD) of the OD600 measurements of extracted dye (V; n = 5), liver and lung metastasis at day 56 (W; n = 5), and survival rate (X; at least six mice were examined in each group). Bars, 200 µm. *, P < 0.05; **, P < 0.01. are thought to reflect the vascular defects in op/op mice, which are characterized by normal sprouting angiogenesis and im paired vascular remodeling. Although VEGF plays a critical role in angiogenic sprouting (26) , MMP2 and MMP9 are gelatinase proteinases with overlapping substrates (e.g., fibro nectin) that function together in some situations such as aortic aneurysms (24) . One of the major questions in our study is whether disordered fibronectin architecture, which is pre sumably caused by the absence of macrophage MMP2 and MMP9, is the primary cause of vascular defects in op/op mice. However, the precise function of specific proteinases is gener ally difficult to discern because of the considerable redundancy of these enzymes (24) . In fact, MMP9 / mice exhibit normal vascular development and normal ECM structures in their developing retina (unpublished data), which is in contrast to the dramatically decreased NVTs observed in the OIR model. Clinical observations of diabetic microvessels in humans have revealed that disordered fibronectin structures are the earliest events preceding various capillary defects (38) . These observa tions also support the idea that disordered fibronectin architec ture accounts for defects associated with impaired vascular remodeling in the op/op retina.
Previous studies have shown that MCSF/cfms signaling promotes the differentiation of circulating monocytes into 
Intraocular injections.
Injections into the vitreous body were performed using 33gauge needles, as described previously (26, 40) . Approximately 1 mg/ml AFS98 or an isotypematched irrelevant rat IgG dissolved in 50 nl of sterile PBS was injected on P1 or P12 (OIR).
Lymphangiography. Functional lymphatic vessels were visualized by injecting 20 µl of Evans blue dye (5 mg/ml; SigmaAldrich) into the hindlimb footpad or the ear, and lymphatic vessels were analyzed via light microscopy. In preparation for the tumor dye efflux experiment, we injected 50 µl of Evans blue dye into tumors and sacrificed animals 2 h later. Approximately 100 mg of tumors were dissected and incubated in 1 ml formamide (to extract the Evans blue dye), and the absorbency was measured at OD600 using a spectrophotometer.
Quantitative RT-PCR analysis. Total RNA was prepared from cultured cells and reverse transcribed using Superscript II (Invitrogen). Quantitative PCR was performed on an ABI 7500 Fast RealTime PCR system using the TaqMan Fast Universal PCR master mix (Applied Biosystems) and a TaqMan Gene Expression Assay mixture containing csf-1 (Mm00432688_m1), csfr-1 (Mm00432689_m1), or vegf-a (Mm00437304_m1). A mouse actin (Mm00607939_s1) mixture served as an endogenous control. Data were analyzed using 7500 Fast System SDS Software 1.3.1. All experiments were performed in quadruplicate and a mean was obtained for each sample. FACS analysis. Dissected tracheas were incubated at 37°C for 30 min in DMEM containing 1% collagenase d (from Clostridium histolyticum; Roche) before dissociation by gentle trituration. Harvested cells were immunostained, followed by purification and analysis using the FACSVantage (BD).
Confocal microscopy. Fluorescence images were obtained using a confocal laserscanning microscope (FV1000; Olympus). Scanning was performed in sequential laser emission mode to avoid scanning at other wavelengths. Cells or substances of interest were quantified in eight (200 µm × 200 µm) fields of view per sample in each scanned image, and the mean of eight fields was determined.
Statistical analysis. Results were expressed as means ± SD. The means of two groups were compared using a twotailed Student's t test. Pvalues <0.05 were considered statistically significant.
Online supplemental material. Fig. S1 shows normal vascular structure in op/op mice at P8 and P90. Fig. S2 shows that MCSF deficiency or MCSF macrophages (13) . However, abundant cfms expression by LYVE1 + macrophages and defective postnatal lymphangio genesis in op/op mice suggests that MCSF also acts on LYVE 1 + macrophages and lymphangiogenesis. The link between the absence of LYVE1 + cells and reduced lymphangiogenesis may be explained by reductions in the secretion of VEGFC, VEGF-D, or other inflammatory cytokines by LYVE1 + macro phages (11, 31, 32) . The significant contribution of BMderived lymphatic endothelial progenitor cells to lymphangiogenesis (39) may be responsible for this link.
Other than MCSF/cfms signaling, VEGF/Flt1 signaling significantly contributes to the recruitment of macrophages and tumor progression in various cancer models (11, (34) (35) (36) . In our osteosarcoma model (in which tumor cells expressed high levels of MCSF, just as in human osteosarcoma), de ficiency in Flt1 tyrosine kinase did not significantly affect tumor progression. These data suggest that tumor progression depends primarily on MCSF/cfms signaling rather than on VEGF/Flt1 signaling. In addition, the Vegfr1 tk / mice in the OIR model did not experience a significant reduction in the amount of NVT or in the number of recruited macrophages (unpublished data). However, decreases in the number of tumorassociated macrophages observed in Vegfr1 tk / mice in other cancer models suggest that VEGF/Flt1 signaling plays an important role in the recruitment of macrophages and that Flt1targeted therapy also holds potential as a tumorselective strategy. It would be interesting to determine the extent to which MCSF/cfms or VEGF/Flt1 signaling affects macro phage recruitment in various other cancer models.
Overall, our data show that MCSF inhibition efficiently suppresses pathological angiogenesis and lymphangiogenesis in mice with ischemic retinopathy and osteosarcoma. This highly selective chemotherapy, which does not affect healthy tissues or induce toxic side effects, may be an ideal treatment for ocular neovascular diseases and cancer.
MATERIALS AND METHODS
Mice and hyperoxia exposure. The C57BL/6 mice (Japan SLC, Inc.), op/op mice (The Jackson Laboratory), MMP9 / mice (The Jackson Labo ratory), and Vegfr1 tk / mice (34, 35) were used. All animal experiments were approved by Keio University and were performed in accordance with the Guidelines of Keio University for Animal and Recombinant DNA ex periments. The P8 mice and nursing mothers used in the OIR model were maintained for 3 d in 85% oxygen and then placed in room air (40) . To ex amine cfms inhibition, mice were subcutaneously injected once daily from P8 to P11 or from P11 to P16 with 50 mg/kg (body weight [BW]) of Ki20227 (27) dissolved in 100 µl methylcellulose or vehicle.
Preparation of whole-mount samples. Isolated eyes, tracheas, and other tis sues were fixed for 20 min in 4% paraformaldehyde (PFA) in PBS and dissected as previously described (31, 40) . Tissues were postfixed and stored in methanol at 20°C. The tissue samples were gradually rehydrated for further analysis.
Whole-mount IHC and ISH. IHC analysis of wholemount samples was performed as previously described (31, 40) . For wholemount retinal ISH, retinas were briefly digested with proteinase K and hybridized with digoxi geninlabeled antisense RNA probes.
Antibodies for IHC. Primary monoclonal antibodies used include hamster anti-PECAM1 (2H8; Millipore), rat anti-PECAM1 (MEC13.3; BD), inhibition does not affect vasoobliteration in OIR model. Fig. S3 shows that various embryonic tissues in op/op mice exhibit normal lymphangiogen esis but lacked LYVE1 + macrophages. Fig. S4 shows that hypoxia, but not Ki20227, induces osteogenic differentiation and decreases proliferation in cultured AX cells. Fig. S5 shows that there is no significant difference be tween Vegfr1 tk +/+ and Vegfr1 tk / in tumor progression when transplanted with AX cells. Online supplemental material is available at http://www.jem .org/cgi/content/full/jem.20081605/DC1.
